These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14615824)

  • 21. Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract.
    Nguyen T; Park JY; Scudiere JR; Montgomery E
    Am J Surg Pathol; 2009 Sep; 33(9):1355-63. PubMed ID: 19542873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil-related gastrointestinal mucosal injury in multivisceral transplantation.
    Delacruz V; Weppler D; Island E; Gonzalez M; Tryphonopoulos P; Moon J; Smith L; Tzakis A; Ruiz P
    Transplant Proc; 2010; 42(1):82-4. PubMed ID: 20172286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
    Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.
    Vanhove T; Kuypers D; Claes KJ; Evenepoel P; Meijers B; Naesens M; Vanrenterghem Y; Cornelis T; Bammens B
    Transpl Int; 2013 Aug; 26(8):813-21. PubMed ID: 23746202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
    Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo Crohn's disease in a renal transplant recipient.
    Halim MA; Said T; Nair P; Schmidt I; Hassan A; Johny KV; Al-Muzairai I; Samhan M; Nampoory MR; Al-Mousawi M
    Transplant Proc; 2007 May; 39(4):1278-9. PubMed ID: 17524953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lessons from a transplant patient with diarrhea, cryptosporidial infection, and possible mycophenolate mofetil-associated colitis.
    Frei P; Weber A; Geier A; Mertens JC; Kohler S; Rogler G; Müllhaupt B
    Transpl Infect Dis; 2011 Aug; 13(4):416-8. PubMed ID: 21615846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycophenolate mofetil reduces tissue damage and inflammation in an experimental model of colitis in rats.
    Zeeh JM; Zorlu ; Riley NE; Hoffmann P; Ruwe M; Goebell H; Gerken G; Dignass AU
    Scand J Gastroenterol; 2001 Jan; 36(1):66-70. PubMed ID: 11218241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycophenolate-induced colitis in a patient with lupus nephritis: a case report and review of the literature.
    Alakkas Z; Gari AM; Makhdoum S; AlSindi EA
    J Med Case Rep; 2024 May; 18(1):229. PubMed ID: 38689344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients.
    Pascual J; Ocaña J; Marcén R; Fernández A; Galeano C; Alarcón MC; Burgos FJ; Villafruela JJ; Ortuño J
    Transplant Proc; 2006 Oct; 38(8):2398-9. PubMed ID: 17097946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
    Tierce JC; Porterfield-Baxa J; Petrilla AA; Kilburg A; Ferguson RM
    Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
    Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
    Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
    Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Infectious complications in using mofetil micofenolate in patients with renal allotransplant].
    Prokopenko EI; Shcherbakova EO; Vatazin AV; Kruglov EE; Pasov SA; Budnikova NE; Agafonova SG; Rusanova EV
    Ter Arkh; 2005; 77(1):67-72. PubMed ID: 15759459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.